The value of a second transurethral resection for T1 bladder cancer
- PMID: 16566814
- DOI: 10.1111/j.1464-410X.2006.06144.x
The value of a second transurethral resection for T1 bladder cancer
Abstract
Objective: To evaluate a series of repeat transurethral resections (TURs) of tumour in patients with T1 bladder cancer, usually used to ensure a complete resection and to exclude the possibility muscle-invasive disease.
Patients and methods: In all, 136 consecutive patients had a second TUR because of a histopathological diagnosis of T1 transitional cell carcinoma (TCC) after their initial TUR. Of the 136 patients, 101 were first presentations and 35 had recurrent tumours. The second TUR was done 4-6 weeks later. The evaluation included the presence of previously undetected residual tumour, changes to histopathological staging/grading, and tumour location.
Results: In all, 71 patients (52%) had residual disease according to findings from specimens obtained during the second TUR. The staging was: no tumour, 65 (48%); Ta, 11 (8%); T1, 32 (24%); Tis, 15 (11%); and > or = T2, 13 (10%). Histopathological changes that worsened the prognosis (>T1 and or concomitant Tis) were found in 21% of patients. Residual malignant tissue was found in the same location as the first TUR in 86% of the patients, and at different locations in 14%. Overall, 28 patients (21% of the original 136) had a radical cystectomy as a consequence of the second TUR findings.
Conclusions: A routine second TUR should be advised in patients with T1 TCC of the bladder, to achieve a more complete tumour resection and to identify patients who should have a prompt cystectomy.
Comment in
-
Is a second transurethral resection necessary in T1 bladder cancer?Nat Clin Pract Urol. 2007 Jan;4(1):12-3. doi: 10.1038/ncpuro0659. Nat Clin Pract Urol. 2007. PMID: 17211416 No abstract available.
Similar articles
-
Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma.BJU Int. 2008 Aug 5;102(5):566-71. doi: 10.1111/j.1464-410X.2008.07637.x. Epub 2008 Apr 11. BJU Int. 2008. PMID: 18410436
-
Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR.BJU Int. 2010 Jan;105(2):202-7. doi: 10.1111/j.1464-410X.2009.08694.x. Epub 2009 Jun 24. BJU Int. 2010. PMID: 19558557
-
Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer?J Urol. 2006 Apr;175(4):1258-61. doi: 10.1016/S0022-5347(05)00689-0. J Urol. 2006. PMID: 16515974 Clinical Trial.
-
Invasive T1 bladder cancer: indications and rationale for radical cystectomy.BJU Int. 2008 Aug;102(3):270-5. doi: 10.1111/j.1464-410X.2008.07743.x. Epub 2008 May 20. BJU Int. 2008. PMID: 18494831 Review.
-
A second-look TUR in T1 transitional cell carcinoma: why?Eur Urol. 2004 May;45(5):539-46; discussion 546. doi: 10.1016/j.eururo.2003.12.016. Eur Urol. 2004. PMID: 15082193 Review.
Cited by
-
Therapeutic benefit of second-look transurethral resection of bladder tumors for newly diagnosed T1 bladder cancer: a single-center experience.Int Urol Nephrol. 2019 Aug;51(8):1335-1342. doi: 10.1007/s11255-019-02172-8. Epub 2019 May 25. Int Urol Nephrol. 2019. PMID: 31129781
-
Application of new technology in bladder cancer diagnosis and treatment.World J Urol. 2009 Jun;27(3):301-7. doi: 10.1007/s00345-009-0387-z. Epub 2009 Feb 22. World J Urol. 2009. PMID: 19234856
-
Wide-field autofluorescence-guided TUR-B for the detection of bladder cancer: a pilot study.World J Urol. 2018 May;36(5):745-751. doi: 10.1007/s00345-017-2147-9. Epub 2017 Dec 6. World J Urol. 2018. PMID: 29214354
-
Presence and predominance of histological grade 3 define cT1HG bladder cancer prognostic groups.Investig Clin Urol. 2022 Jan;63(1):21-26. doi: 10.4111/icu.20210386. Investig Clin Urol. 2022. PMID: 34983119 Free PMC article.
-
Dysuria therapeutic agents as an independent prognostic factor for the primary recurrence of non-muscle invasive bladder cancer: a propensity score matching study.J Int Med Res. 2021 Aug;49(8):3000605211037478. doi: 10.1177/03000605211037478. J Int Med Res. 2021. PMID: 34407681 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical